Besides, 27% of hepatocellular carcinoma patients (4 out of 15) showed confirmed tumor responses, and in the pancreatic adenocarcinoma cohort, there was one confirmed and two unconfirmed responses among 15 patients.388 This regimen also led to decreased populations of effector Tregs and increased CD8+ T cells within the TME.388 The discrepancy between the two trials underscores the critical role of the tumor microenvironment and the specific mechanisms of action of the therapeutic agents used. Here, CD8A is linked to neoplasm.